Advertisement
Organisation › Details
Novo REPAIR Impact Fund (Replenishing and Enabling the Pipeline for Anti-Infective Resistance)
Novo Holdings launches an impact fund commissioned by the Novo Nordisk Foundation with a total budget of USD 165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance. The fund will focus on priority pathogens as defined by the World Health Organization and the United States Centers for Disease Control and Prevention, a catalogue of 12 families of bacteria that pose the greatest threat to human health. The fund is expected to invest USD 20 million to 40 million per year over 3–5 years in about 20 projects in Europe and the United States, which is anticipated to yield at least one new therapy reaching the market. New approaches to combat antimicrobial resistance urgently need to be developed. Already, more than 700,000 people die each year from infections resistant to most or all antibiotics, and the number is increasing by the day. Antimicrobial resistance is projected to kill more people than cancer does by 2050, which would reduce global economic output by between 2% and 3.5% and severely cripple modern medical and surgical advances. The Novo Nordisk Foundation is commissioning the initiative, and Novo Holdings is executing it. REPAIR is an acronym: Replenishing and Enabling the Pipeline for Anti-Infective Resistance. Read more and watch the project video: www.repair-impact-fund.com *
Start | 2018-02-27 established | |
Group | Novo Group (Group) | |
Industry | venture capital | |
Industry 2 | anti-infective drug | |
Person | Engel, Aleks (Novo 201510 Asset Director at Novo A/S) | |
Region | København (Copenhagen) | |
Country | Denmark | |
City | n. a. København | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Currency | USD | |
Annual sales | 165,000,000 (funds, managed (2018) 2018-02-27) | |
* Document for »About Section«: Novo Holdings A/S. (2/27/18). "Press Release: Novo Holdings Launches USD 165m Impact Fund to Combat Antimicrobial Resistance". Copenhagen. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Novo Group (Group)
- [1] CMS Hasche Sigle. (3/26/24). "Press Release: CMS Advises Sellers of Cardior Pharmaceuticals on Potential Acquisition by Novo Nordisk". Munich....
- [2] Cardior Pharmaceuticals GmbH. (3/25/24). "Press Release: Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease". Bagsværd & Hannover....
- [3] Novo Nordisk A/S. (1/4/24). "Press Release: Novo Nordisk Enters into Research Collaborations with Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases". Bagsværd, Cambridge, MA & Somerville, MA....
- [4] LimmaTech Biologics AG. (10/9/23). "Press Release: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections". Schlieren....
- [5] Novo Nordisk A/S. (9/25/23). "Press Release: Valo Health and Novo Nordisk to Collaborate to Discover and Develop Novel Treatments for Cardiometabolic Diseases Using Human Data and Artificial Intelligence". Bagsværd & Boston, MA....
- [6] Embark Laboratories ApS. (8/30/23). "Press Release: Novo Nordisk Acquires Embark Biotech, including Its Lead Asset Targeting Obesity and other Cardiometabolic Diseases". Copenhagen....
- [7] Novo Nordisk A/S. (8/10/23). "Press Release: Novo Nordisk to Acquire Inversago Pharma to Develop New Therapies for People Living with Obesity, Diabetes and other Serious Metabolic Diseases". Bagsværd & Montreal....
- [8] Bactolife A/S. (8/8/23). "Press Release: Bactolife Raises EUR 30 Million in Series A Financing". Copenhagen....
- [9] BioGeneration Ventures B.V.. (7/13/23). "Press Release: BioGeneration Ventures Closes BGV Fund V at €150 Million". Naarden....
- [10] EQT AB. (6/21/23). "Press Release: EQT Private Equity to Sell Ellab, Following Transformation into a Leading Validation & Monitoring Provider for the Biotech and Pharmaceutical Industries"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top